Senate Bill Decriminalizing Psychedelics Could Help Reverse Some 'War on Drugs' Impacts

FN Media Group Presents Microsmallcap.com Market Commentary

NEW YORK, Sept. 22, 2021 /PRNewswire/ -- The global need for effective mental health treatment has led to the growing push for the legalization of psychedelic therapies, pushing the market into the mainstream. Last week, Michigan Senator Jeff Irwin introduced legislation that would decriminalize the use of mescaline and psilocybin. If passed, Senate Bill 631 would allow the possession, cultivation, and delivery of mescaline and psilocybin. In addition, the bill will allow practitioners to charge for counseling and spiritual guidance if they use an entheogenic plant or fungus. This legislation coupled with the growing body of research that proves the effectiveness of psychedelics against mental health conditions is among the reasons pushing the psychedelic market towards $69 billion by 2026 . As this happens, companies like Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF), Cybin Inc. (NEO:CYBN), Compass Pathways (NASDAQ:CMPS), PhamaTher (OTCQB:PHRRF) (CSE:PHRM), and Mind Medicine (MindMed) (NASDAQ:MNMD) (NEO:MMED) are pushing R&D efforts to develop and test psychedelic therapies for different health conditions. 

Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to evaluate its clinical candidate TRP-8802 in a Phase 2a clinical study for the treatment of eating disorders.

The pharmaceutical company, which develops psilocybin-based compounds for conditions with unmet medical needs, submitted the application weeks after the company completed psychotherapy training for the upcoming Phase 2a trial. The Phase 2a trial, which is being conducted at the University of Florida with Jennifer Miller, M.D, will evaluate Tryp's oral formulation of synthetic psilocybin in combination with psychotherapy.

Tryp's IND application has details on the safety of the drug product, the study protocol, informed consent information for patients, and additional information. The Phase 2a study expects to enroll ten patients with a variety of overeating disorders including binge eating disorder, hypothalamic obesity, and Prader-Willi syndrome. The company expects that the psilocybin oral formulation will increase neuroplasticity and therefore, help create healthy neural patterns of hunger and eating.

Tryp Therapeutics anticipates beginning the study in Q4 2021 following a favorable review from the FDA. Commenting on the IND submission, Jennifer Miller, M.D. said, "The submission of this IND represents hundreds of hours of preparation, design, and coordination as we pursue a leading-edge treatment of psilocybin with psychotherapy."

Greg McKee, Chairman and CEO of Tryp Therapeutics also commented, "This IND submission marks the most important milestone the company has achieved to date and will be critical to identifying patient responses to the active ingredient, consistent with that of our proprietary drug candidate, TRP-8803, that will be used in Phase 2b trials and beyond."

The company also intends to make additional IND submissions in the coming months for clinical trials in chronic pain and eating disorders with at least two Phase 2a clinical trials starting before the end of the year.  For more information on Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF), click here.

These Companies are Advancing Psychedelic Research for Conditions with Unmet Needs

Cybin Inc. (NEO:CYBN) recently filed applications for two additional international patents which, once approved, will give the company patent coverage in 153 countries for each of the patents. The patent applications, according to the company, will strengthen the CYB005 program, which is focused on developing therapies for resistant psychiatric disorders and provide a basis for future research. In addition, the patent applications secure the company's rights to apply for national patents in treaty member jurisdictions and key markets, thus supporting Cybin's strategic objectives.

Meanwhile, mental health company Compass Pathways (NASDAQ:CMPS), has acquired an IP portfolio that includes patent applications for various psychedelic and empathogenic substances. The IP portfolio was developed in collaboration with Dr. Matthias Grill PhD., CEO and Founder MiKHAL GmbH who has been involved in psychedelic chemistry research for over 15 years. Grill will be working with Compass on an exclusive research project to develop new product candidates. The agreement to work with Dr. Matthias and MiKHAL GmbH will strengthen Compass' IP and development portfolio with new compounds that the company will move to clinical development towards helping patients with unmet mental healthcare needs.

Clinical stage psychedelics biotech company PhamaTher (OTCQB:PHRRF) (CSE:PHRM) has received the Orphan Drug Designation from the U.S. Food and Drug Administration for ketamine in the treatment of Amytrophic Lateral Sclerosis (ALS). This designation allows the company to proceed to its Phase 2 clinical study on patients suffering from ALS and validates the effectiveness of ketamine as an effective therapy for neurologic disorders. The designation is a major milestone for the company, which is targeting a therapy that increases the survival rate for approximately 50,000 people in the US who are diagnosed with the life-threatening condition.

Mind Medicine (MindMed) (NASDAQ:MNMD) (NEO:MMED), a biotech company involved in the development of psychedelic-based therapies, and BioXcel, a biopharmaceutical company published BioXcel's international patent for detecting and preventing the early onset of agitation in patients susceptible to highly agitated behavior due to acute and chronic neurological illness. The patent covers a method for caregivers to detect signs of impending agitation, thus preparing them to treat the patient before these symptoms develop into agitation. Through this method, caregivers can reduce the need for intensive intervention by de-escalating the agitated behavior earlier.

R&D initiatives will be important not only in developing therapies for unmet medical needs but in providing science-backed data that will inform future legislation. Companies like Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) are making it possible for psychedelics to become recognized as therapies that can be used in the treatment of many conditions.

Disclaimer:  Microsmallcap.com (MSC) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Tryp Therapeutics.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.

 Media Contact:

 FN Media Group, LLC
 info@financialnewsmedia.com 
 +1(561)325-8757